In the latest trading session,, 6.05 million Unity Biotechnology Inc (NASDAQ:UBX) shares changed hands as the company’s beta touched 1.06. With the company’s most recent per share price at $0.90 changing hands around $0.2 or 29.00% at last look, the market valuation stands at $15.51M. UBX’s current price is a discount, trading about -244.44% off its 52-week high of $3.10. The share price had its 52-week low at $0.66, which suggests the last value was 26.67% up since then. When we look at Unity Biotechnology Inc’s average trading volume, we note the 10-day average is 0.14 million shares, with the 3-month average coming to 172.93K.
Analysts gave the Unity Biotechnology Inc (UBX) stock a consensus recommendation rating of Buy, calculated at a mean rating of 2.00. If we narrow down to specifics, the data shows that 0 out of 3 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended UBX as a Hold, 3 felt it is a Buy and 0 rated the stock as Underweight. Unity Biotechnology Inc’s EPS for the current quarter is expected to be -0.21.
Unity Biotechnology Inc (NASDAQ:UBX) trade information
Instantly UBX is in green as seen in intraday trades today. With action 25.97%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -7.74%, with the 5-day performance at 25.97% in the green. However, in the 30-day time frame, Unity Biotechnology Inc (NASDAQ:UBX) is -1.45% down. Looking at the short shares, we see there were 0.75 million shares sold at short interest cover period of 5.31 days.
The consensus price target for the stock as assigned by Wall Street analysts is 2.5, meaning bulls need an upside of 64.0% from its recent market value. According to analyst projections, UBX’s forecast low is 1 with 4 as the target high. To hit the forecast high, the stock’s price needs a -344.44% plunge from its current level, while the stock would need to soar -11.11% for it to hit the projected low.
According to analysts, the company will likely register a growth in its current quarter sales, forecast at 0.00%. The estimates for the next quarter sales put growth at 0.00%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 39.36%. The 2025 estimates are for Unity Biotechnology Inc earnings to increase by 30.13%, but the outlook for the next 5-year period is at 28.14% per year.
UBX Dividends
Unity Biotechnology Inc is expected to release its next quarterly earnings report on 2025-Apr-21.
Unity Biotechnology Inc (NASDAQ:UBX)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 1.90% of Unity Biotechnology Inc shares while 17.19% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 17.53%.
Among Mutual Funds, the top two as of Mar 31, 2025 were VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund . With 478.31 shares estimated at $0.44 million under it, the former controlled 2.78% of total outstanding shares. On the other hand, VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund held about 1.13% of the shares, roughly 194.78 shares worth around $0.18 million.
